To Our Stockholders, Employees and Friends: In 2013, Gilead made major advances across our areas of therapeutic focus, significantly expanded the company’s global reach, delivered medicines to a record number of patients and announced the strongest revenues in the company’s history.

The approval and introduction of Sovaldi® as a treatment for chronic hepatitis C virus (HCV) infection stands out among Gilead’s 2013 accomplishments. For millions of people living with HCV, Sovaldi®-based therapy may offer a cure with a significantly shorter and less burdensome course of treatment. Gilead also advanced new HIV products and research during the past year and made significant progress in oncology, the company’s newest therapeutic area of focus. Fuelled by strong commercial performance, Gilead’s financial position is stronger than ever, with record total revenues in 2013 of $11.2 billion.

Each of the milestones and accomplishments of the past year exemplify Gilead’s mission of developing and delivering medicines that redefine how serious diseases are treated. Our accomplishments also exemplify the dedication of Gilead’s 6,650 employees, who collaborate with the medical community, partners and each other to understand and to pursue what’s in the best interest of patients.

A New Era in Hepatitis C Treatment, Continued Focus on Liver Diseases

On December 6, Sovaldi, a once-daily nucleotide analog polymerase inhibitor for the treatment of chronic HCV infection, was approved by the U.S. Food and Drug Administration (FDA) as a component of a combination antiviral treatment regimen. This milestone is the culmination of many years of work—developing the molecule, designing clinical trials to best define its use across various genotypes and patient populations, and ensuring involvement of the medical community, which has long awaited a new treatment. In addition, Gilead worked quickly to build an experienced commercial and medical affairs organization prepared to support the introduction of Sovaldi around the world.

Sovaldi’s efficacy has been established in patients with HCV genotypes 1, 2, 3 or 4 infection. In certain Phase 3 studies in combination with other medicines, Sovaldi achieved cure rates as high as 90 percent, while shortening the duration of therapy from 24-48 weeks to 12 weeks in some patients and altogether eliminating the need for debilitating interferon injections in other patients.

The product was approved in Canada in mid-December and regulatory filings in Turkey, Switzerland, Australia and New Zealand set the stage for additional approvals in 2014. In the European Union, it received a positive opinion from the Committee for Medicinal Products for Human Use in late November and full European Commission approval in January 2014. In Japan, an agreement with the Japanese regulatory agency (Pharmaceuticals and Medical Devices Agency) was established, and Phase 3 clinical trials of sofosbuvir in combination with other medicines were initiated and fully enrolled, with the goal of submitting a regulatory filing in the second half of 2014.

Gilead’s operations in Japan were formally established in November and full European Commission approval in January 2014. In Japan, an agreement with the Japanese regulatory agency (Pharmaceuticals and Medical Devices Agency) was established, and Phase 3 clinical trials of sofosbuvir in combination with other medicines were initiated and fully enrolled, with the goal of submitting a regulatory filing in the second half of 2014.

Gilead’s operations in Japan were formally established in November and full European Commission approval in January 2014. In Japan, an agreement with the Japanese regulatory agency (Pharmaceuticals and Medical Devices Agency) was established, and Phase 3 clinical trials of sofosbuvir in combination with other medicines were initiated and fully enrolled, with the goal of submitting a regulatory filing in the second half of 2014.

Gilead continues its efforts to improve treatment for HIV and expanding access to therapy for patients around the world. Strilver® became the leading prescribed regimen for treatment-naive HIV patients in the United States, received European Commission approval in May and was subsequently launched in the United Kingdom, Austria, Germany, Luxembourg, Ireland, Spain, Poland, Switzerland, the Netherlands and all five Nordic countries. Uptake of this product increased significantly throughout the year in the United States and Europe. Data characterizing the efficacy and safety of Strilver over three years were presented in October at the annual conference of the European AIDS Clinical Society. Gilead’s second single tablet regimen for HIV, Complera®, received a prescribing label expansion in the United States to include suppressed patients switching from a stable antiretroviral treatment regimen. In Europe, where it is marketed as Evipan®, the product received a similar expanded indication.

Tybost®, a boosting agent for certain protease inhibitor-based regimens, and Viekira® an integrase inhibitor, were approved in the European Union and Canada in the second half of 2013. Following receipt of a Complete Response Letter from FDA in April 2013, Gilead is working to resubmit applications for both of these products in the United States. In January 2013, a large-scale Phase 3 clinical program was initiated for Gilead’s newest single tablet regimen of TAF combined with elvitegravir, cobicistat and emtricitabine. Phase 2 data for the TAF-based single tablet regimen presented at the 13rd International Conference on Antiretroviral Agents and Chemotherapy in September showed that it was similar to Strilver in efficacy, with what appears to be a more favorable safety profile in terms of renal and bone indicators. These data support the potential of TAF to become a key component of Gilead’s next-generation single tablet regimens. Initial results from the large-scale Phase 3 program are anticipated in early 2015.

To Our Stockholders, Employees and Friends: In 2013, Gilead made major advances across our areas of therapeutic focus, significantly expanded the company’s global reach, delivered medicines to a record number of patients and announced the strongest revenues in the company’s history.

The approval and introduction of Sovaldi® as a treatment for chronic hepatitis C virus (HCV) infection stands out among Gilead’s 2013 accomplishments. For millions of people living with HCV, Sovaldi®-based therapy may offer a cure with a significantly shorter and less burdensome course of treatment. Gilead also advanced new HIV products and research during the past year and made significant progress in oncology, the company’s newest therapeutic area of focus. Fuelled by strong commercial performance, Gilead’s financial position is stronger than ever, with record total revenues in 2013 of $11.2 billion.

Each of the milestones and accomplishments of the past year exemplify Gilead’s mission of developing and delivering medicines that redefine how serious diseases are treated. Our accomplishments also exemplify the dedication of Gilead’s 6,650 employees, who collaborate with the medical community, partners and each other to understand and to pursue what’s in the best interest of patients.

A New Era in Hepatitis C Treatment, Continued Focus on Liver Diseases

On December 6, Sovaldi, a once-daily nucleotide analog polymerase inhibitor for the treatment of chronic HCV infection, was approved by the U.S. Food and Drug Administration (FDA) as a component of a combination antiviral treatment regimen. This milestone is the culmination of many years of work—developing the molecule, designing clinical trials to best define its use across various genotypes and patient populations, and ensuring involvement of the medical community, which has long awaited a new treatment. In addition, Gilead worked quickly to build an experienced commercial and medical affairs organization prepared to support the introduction of Sovaldi around the world.

Sovaldi’s efficacy has been established in patients with HCV genotypes 1, 2, 3 or 4 infection. In certain Phase 3 studies in combination with other medicines, Sovaldi achieved cure rates as high as 90 percent, while shortening the duration of therapy from 24-48 weeks to 12 weeks in some patients and altogether eliminating the need for debilitating interferon injections in other patients.

The product was approved in Canada in mid-December and regulatory filings in Turkey, Switzerland, Australia and New Zealand set the stage for additional approvals in 2014. In the European Union, it received a positive opinion from the Committee for Medicinal Products for Human Use in late November and full European Commission approval in January 2014. In Japan, an agreement with the Japanese regulatory agency (Pharmaceuticals and Medical Devices Agency) was established, and Phase 3 clinical trials of sofosbuvir in combination with other medicines were initiated and fully enrolled, with the goal of submitting a regulatory filing in the second half of 2014. Gilead’s operations in Japan were formally established in February 2014. Also underway is the clinical development of the pan-genotypic NS5A inhibitor, GS-5816, which may have the potential to simplify therapy for all HCV patients, irrespective of viral genotype.

In the area of chronic hepatitis B, Gilead initiated a Phase 3 program for tenofovir alafenamide (TAF), a novel, low-dose prodrug of tenofovir that has the potential to optimize clinical efficacy, safety and tolerability relative to existing chronic hepatitis B virus (HBV) therapies. For most patients with chronic hepatitis B, life-long antiviral therapy is required. Curing HBV infection is the ultimate goal and Gilead is pursuing novel therapies and approaches such as oral medicines and therapeutic vaccines that may provide finite treatment for patients.

Innovating in HIV Medicine

Gilead continues its efforts to improve treatment for HIV and expanding access to therapy for patients around the world. Strilver® became the leading prescribed regimen for treatment-naive HIV patients in the United States, received European Commission approval in May and was subsequently launched in the United Kingdom, Austria, Germany, Luxembourg, Ireland, Spain, Poland, Switzerland, the Netherlands and all five Nordic countries. Uptake of this product increased significantly throughout the year in the United States and Europe. Data characterizing the efficacy and safety of Strilver over three years were presented in October at the annual conference of the European AIDS Clinical Society. Gilead’s second single tablet regimen for HIV, Complera®, received a prescribing label expansion in the United States to include suppressed patients switching from a stable antiretroviral treatment regimen. In Europe, where it is marketed as Evipan®, the product received a similar expanded indication.

Tybost®, a boosting agent for certain protease inhibitor-based regimens, and Viekira® an integrase inhibitor, were approved in the European Union and Canada in the second half of 2013. Following receipt of a Complete Response Letter from FDA in April 2013, Gilead is working to resubmit applications for both of these products in the United States. In January 2013, a large-scale Phase 3 clinical program was initiated for Gilead’s newest single tablet regimen of TAF combined with elvitegravir, cobicistat and emtricitabine. Phase 2 data for the TAF-based single tablet regimen presented at the 13rd International Conference on Antiretroviral Agents and Chemotherapy in September showed that it was similar to Strilver in efficacy, with what appears to be a more favorable safety profile in terms of renal and bone indicators. These data support the potential of TAF to become a key component of Gilead’s next-generation single tablet regimens. Initial results from the large-scale Phase 3 program are anticipated in early 2015.
A pivotal Phase 3 clinical trial was recently initiated for the novel JAK inhibitor mormelotinib for the treatment of myelofibrosis, a life-threatening bone marrow disorder. Mormelotinib came to Gilead with the acquisition of YM Biologics, Inc., which was completed in February 2013.

Progress in Cardiovascular and Respiratory Disease

Gilead’s commercial products for cardiovascular and respiratory diseases together exceeded $1 billion in annual revenues for the first time in 2013. In the area of cardiovascular disease, data from a Phase 4 trial of fluvastatin showed a reduced incidence of chest pain among chronic angina patients with type 2 diabetes. Phase 3 studies of fluvastatin in type 2 diabetes are ongoing, and data should become available in 2014. In August 2013, Letairis®, an endothelin receptor antagonist (ERA) medicine for the treatment of pulmonary arterial hypertension (PAH), received a favorable change to the product’s Risk Evaluation and Mitigation Strategy (REMS). As a consequence of this new modification, only females of reproductive potential will have to enroll into and be monitored regularly through the Letairis REMS program, which greatly lessens the burden on prescribers and the majority of patients. Letairis is now the most frequently prescribed ERA therapy for newly diagnosed PAH patients.

During 2013, Cosyntropin, an orally administered peptide for the treatment of hypogonadism, was approved in the United States and the European Union for Gilead’s lead oncology product, letrozole citrate. Letrozole citrate, a nonsteroidal aromatase inhibitor (NSAI), is being studied in various Phase 2 studies for the treatment of hormone receptor-positive breast cancer and prostate cancer. Gilead is also advancing its oncology pipeline clinical studies in collaboration with its strategic alliance partner, Nektar Therapeutics.

Addressing Future Patient Needs

To support the progress Gilead made in drug development and commercialization in 2013, Gilead’s international presence expanded with measured growth in Asia-Pacific, Latin America and Eastern Europe, through the establishment of new affiliate operations in South Africa, Russia and the Czech Republic. Gilead’s growing global operations will allow the company to reach more patients than ever before.

I would like to thank our shareholders for their ongoing support, our Board of Directors for its continued guidance and our employees, partners and stakeholders for their contributions.

All of us at Gilead look forward to further exciting developments in 2014, as we work to provide innovative therapeutic options for people with life-threatening diseases around the world.

John C. Martin, PhD
Chairman and Chief Executive Officer

Forward-Looking Statement

The Annual Report includes forward-looking statements regarding our clinical studies and product candidates, including the anticipated timing and achievement of certain development milestones, regulatory filings and product launches. Such statements are predictions and involve risks and uncertainties such that actual results may differ materially. Please refer to Gilead’s Annual Report on Form 10-K for the year ended December 31, 2013 attached to this report for the risks and uncertainties affecting Gilead’s business. Gilead disclaims any obligation to update any forward-looking statements in this report.
**Marketed Products**

<table>
<thead>
<tr>
<th>HIV/AIDS</th>
<th>HIV/AIDS (CONT)</th>
<th>CARDIOVASCULAR</th>
</tr>
</thead>
<tbody>
<tr>
<td><em>ATRIPLIA</em>&lt;br&gt;EFAVirenz 600 MG/Etrimetibenine 200 MG/Tenofovir Disoprocol Pumamate 300 MG&lt;br&gt;HIV/AIDS&lt;br&gt;BRISTOL-MYERS SQUIBB COMPANY (U.S., WESTERN EUROPE, CANADA)&lt;br&gt;MERCK &amp; CO., INC. (REST OF WORLD)</td>
<td><em>VITEKA</em>&lt;br&gt;ELVITEGRAVIR 85 MG AND 150 MG&lt;br&gt;HIV/AIDS</td>
<td><em>LETAIRIS</em>&lt;br&gt;AMBRESINER 5 MG AND 10 MG&lt;br&gt;PULMONARY ARTERIAL HYPERTENSION (WHO GROUP I)&lt;br&gt;GLAXONTHOMLINE INC. (OUTSIDE OF THE U.S.) MARKETED AS VOLIBRIS® OUTSIDE OF THE U.S.</td>
</tr>
<tr>
<td><em>COMPLERA</em>&lt;br&gt;ETRIMETIBINE 200 MG/EFAVIRENZ 20 MG/TENOFOVIR DISOPROCOL PUMAMATE 300 MG&lt;br&gt;HIV/AIDS&lt;br&gt;JANSEN-CIBA-ELGAL (SELECT MARKETS) MARKETED AS EVIPLERA® IN EUROPE</td>
<td></td>
<td>LEXISCAN®&lt;br&gt;REGADENOSON INJECTION 0.4 MG&lt;br&gt;PULMONARY ARTERIAL HYPERTENSION ASTELLAS PHARMA INC. (U.S., CANADA) RAMOSCAN (EUROPE AND SELECT OTHER MARKETS)</td>
</tr>
<tr>
<td><em>EMTRIVA</em>&lt;br&gt;ETRIMETIBINE 200 MG&lt;br&gt;HIV/AIDS&lt;br&gt;JAPAN TOBACCO INC. (JAPAN)</td>
<td></td>
<td><em>PANEXA</em>&lt;br&gt;RANDOLIZINE 500 MG AND 1000 MG&lt;br&gt;CHRONIC ANGINA MENARINI GROUP (EUROPE AND SELECT OTHER MARKETS)</td>
</tr>
<tr>
<td><em>STRIHLD</em>&lt;br&gt;ELVITEGRAVIR 150 MG/COBICISTAT 150 MG/ETRIMETIBINE 200 MG/TENOFOVIR DISOPROCOL PUMAMATE 300 MG&lt;br&gt;HIV/AIDS&lt;br&gt;JAPAN TOBACCO INC. (JAPAN)</td>
<td></td>
<td><em>AMBRISOME</em>&lt;br&gt;AMPHOTERICIN B LIPOSOME FOR INJECTION 50 MG/VIAL&lt;br&gt;SEVERE FUNGAL INFECTIONS ASTELLAS PHARMA INC. (U.S., CANADA) DAIICHI SANKYO PHARMACEUTICAL CO., LTD. (JAPAN)</td>
</tr>
<tr>
<td><em>TRUVADA</em>&lt;br&gt;ETRIMETIBINE 200 MG/TENOFOVIR DISOPROCOL PUMAMATE 300 MG&lt;br&gt;HIV/AIDS&lt;br&gt;JAPAN TOBACCO INC. (JAPAN)</td>
<td></td>
<td><em>MACUGEN</em>&lt;br&gt;PEGAPTANIB SODIUM INJECTION 0.3 MG&lt;br&gt;NEOVDASCULAR (VIT) AGE-RELATED MACULAR DEGENERATION EYETECH, INC. (U.S.) Pfizer Inc. (OUTSIDE U.S.)</td>
</tr>
<tr>
<td><em>TYBOST</em>&lt;br&gt;COCICISTAT 150 MG&lt;br&gt;HIV/AIDS</td>
<td></td>
<td>VISTIDE®&lt;br&gt;CIDOFOVIR INJECTION 3.75 MG/VIAL&lt;br&gt;CNS TRINFECTS IN PATIENTS WITH AIDS</td>
</tr>
</tbody>
</table>
| VIREAD®<br>TENOFOVIR DISOPROCOL PUMAMATE 300 MG<br>HIV/AIDS<br>JAPAN TOBACCO INC. (JAPAN) | | *

*Tybost and Vitekta have received marketing authorization in the European Union only at this time. Images shown do not represent actual size. For other dosage strengths see full prescribing information.*

**Liver Diseases**

- **HEPSERA®**<br>ADENOVIR DRIPOXIL 10 MG<br>CHRONIC HEPATITIS B<br>GLAXONTHOMLINE INC. (CHINA, JAPAN, SAUDI ARABIA)

- **SOVALDI®**<br>SOFOSBUVIR 400 MG<br>CHRONIC HEPATITIS C

- **VIREAD®**<br>TENOFOVIR DISOPROCOL PUMAMATE 300 MG<br>CHRONIC HEPATITIS B<br>GLAXONTHOMLINE INC. (CHINA)

**Respiratory**

- **CAYSTON®**<br>AZITHROMYCIN FOR INHALATION SOLUTION 75 MG/VIAL<br>CYSTIC FIBROSIS, PSEUDOMONAS ABUGINOSA

- **TAMIFLU®**<br>OSITAMIB PHOSPHATE 75 MG<br>INFLUENZA A & B<br>F. HOFFMANN-LA ROCHEL LTD (WORLDWIDE)

**Other**

- **AMBRISOME®**<br>AMPHOTERICIN B LIPOSOME FOR INJECTION 50 MG/VIAL<br>SEVERE FUNGAL INFECTIONS ASTELLAS PHARMA INC. (U.S., CANADA) DAIICHI SANKYO PHARMACEUTICAL CO., LTD. (JAPAN)

- **MACUGEN®**<br>PEGAPTANIB SODIUM INJECTION 0.3 MG<br>NEOVDASCULAR (VIT) AGE-RELATED MACULAR DEGENERATION EYETECH, INC. (U.S.) Pfizer Inc. (OUTSIDE U.S.)

- **VISTIDE®**<br>CIDOFOVIR INJECTION 3.75 MG/VIAL<br>CNS TRINFECTS IN PATIENTS WITH AIDS
ONCOLOGY/INFLAMMATION

**EU APPROVAL AS TYBOST®; U.S. REGULATORY SUBMISSION**

**COBICISTAT (PHARMACOKINETIC ENHANCER)**
**POTENTIAL INDICATION: HIV/AIDS**

**EU APPROVAL AS VITEKTA®, U.S. REGULATORY SUBMISSION**

**ELVITEGRA VIR (INTEGRASE INHIBITOR)**
**POTENTIAL INDICATION: HIV/AIDS**

**PHASE 3**
**SINGLE TABLET REGIMEN OF ELVITEGRA VIR/COBICISTAT/EMTRICITABINE/ TENOFOVIR ALAFENAMIDE**
**POTENTIAL INDICATION: HIV/AIDS**

**PHASE 2**
**SINGLE TABLET REGIMEN OF DARUNA VIR/COBICISTAT/EMTRICITABINE/ TENOFOVIR ALAFENAMIDE**
**POTENTIAL INDICATION: HIV/AIDS**

**LIVER DISEASES**

**CHRONIC HEPATITIS C**
**U.S. REGULATORY SUBMISSION**
**FIXED-DOSE COMBINATION OF LEDIPASVIR AND SOFOSBUVIR**
**(NS5A INHIBITOR/NUCLEOTIDE NS5B INHIBITOR)**
**POTENTIAL INDICATION: CHRONIC HCV INFECTION**

**PHASE 2**
**FIXED-DOSE COMBINATION OF SOFOSBUVIR AND GS-5816**
**(PAN-GENOTYPIC NS5B/NS5A INHIBITORS)**
**POTENTIAL INDICATION: CHRONIC HCV INFECTION**

**GS-9973**
**(SYK INHIBITOR)**
**POTENTIAL INDICATION: HEMATOLOGICAL MALIGNANCIES**

**PHASE 1**
**GS-5745**
**(MMP9 MAB INHIBITOR)**
**POTENTIAL INDICATION: SOLID TUMORS**

**RESPIRATORY DISEASE**

**PHASE 2**
**SIMTUZUMAB**
**(MONOCLONAL ANTIBODY)**
**POTENTIAL INDICATION: IDIOPATHIC PULMONARY FIBROSIS**

**PHASE 1**
**GS-4774**
**(T ARMOGEN T CELL IMMUNITY STIMULATOR)**
**POTENTIAL INDICATION: CHRONIC HBV INFECTION**

**PHASE 1**
**GS-9620**
**(TLR-7 AGONIST)**
**POTENTIAL INDICATION: CHRONIC HBV INFECTION**

**PHASE 3**
**TENOFOVIR ALAFENAMIDE**
**(NUCLEOTIDE REVERSE TRANSCRIPTASE INHIBITOR)**
**POTENTIAL INDICATION: CHRONIC HBV INFECTION**

**PHASE 2**
**GS-4997**
**(ASK-1 INHIBITOR)**
**POTENTIAL INDICATION: DIABETIC NEPHROPATHY**

**PHASE 2**
**GS-5806**
**(FUSION INHIBITOR)**
**POTENTIAL INDICATION: RESPIRATORY SYNCYTIAL VIRUS**

**PHASE 2**
**SIMTUZUMAB**
**(MONOCLONAL ANTIBODY)**
**POTENTIAL INDICATION: IDIOPATHIC PULMONARY FIBROSIS**